P Bironzo
Overview
Explore the profile of P Bironzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
673
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donini C, Galvagno F, Rotolo R, Massa A, Merlini A, Scagliotti G, et al.
Br J Cancer
. 2023 Jul;
129(9):1409-1416.
PMID: 37474722
Blocking the inhibitory receptor PD-1 on antitumour T lymphocytes is the main rationale underlying the clinical successes of cancer immunotherapies with checkpoint inhibitor (CI) antibodies (Abs). Besides this main paradigm,...
2.
Manganaro L, Bianco S, Bironzo P, Cipollini F, Colombi D, Cora D, et al.
Sci Rep
. 2023 May;
13(1):7759.
PMID: 37173325
Recent advances in machine learning research, combined with the reduced sequencing costs enabled by modern next-generation sequencing, paved the way to the implementation of precision medicine through routine multi-omics molecular...
3.
Morfouace M, Novello S, Stevovic A, Dooms C, Janzic U, Berghmans T, et al.
Sci Rep
. 2022 May;
12(1):8342.
PMID: 35585228
Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients...
4.
Remon J, Hendriks L, Bironzo P
Ann Oncol
. 2021 Dec;
33(2):123-125.
PMID: 34883215
No abstract available.
5.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, et al.
Ann Oncol
. 2019 May;
30(8):1321-1328.
PMID: 31125062
Background: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly...
6.
Marandino L, Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, et al.
Ann Oncol
. 2018 Oct;
29(12):2288-2295.
PMID: 30304498
Quality of life (QoL) is a relevant end point and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as...
7.
Scagliotti G, Bironzo P, Vansteenkiste J
Cancer Treat Rev
. 2015 May;
41(6):465-75.
PMID: 25936526
Chemotherapy is currently the standard of care for non-oncogene-driven advanced non-small cell lung cancer (NSCLC). Due to improvements in chemotherapeutic choices and supportive care, patients currently typically undergo multiple lines...